CliniSciences Group, a European distributor of reagents and equipment for scientific research and medical diagnosis, has acquired Oncomedics, a French biotechnology company specialising in the personalisation of cancer treatments.
Joint efforts between Generon, Erganeo and the academic lab headed by Véronique Baud, in the field of research to facilitate the diagnosis of triple negative breast cancer have yielded new findings that make it easier to classify and predict degree of aggressiveness.